Ehud (Udi) Netzer, PhD – Board Director, Interim Chairman
Dr. Netzer is a seasoned technology leader with over 35 years of experience covering all phases of basic research, product development, engineering, commercialization and senior management.
During the past 15 years Dr. Netzer served as CEO of Orbit Systems, Head of R&D of the Israel Atomic Energy Commission, Chairman of Rotem Industries, and Director General of Nuclear Research Center Negev. Prior to that he spent 25 years at Rafael, moving up through the ranks to become Senior VP and Head of Division.
Dr. Netzer received his BSc and MSc degrees in Mechanical Engineering from the Technion (with distinction) and holds a PhD degree in Mechanical Engineering from Stanford University. Dr. Netzer is a graduate of the Advanced Management Program of Harvard Business School.
Sagi Brink-Danan, MSc, MBA – Chief Executive Officer, Board Director
Sagi brings over 17 years of entrepreneurial and executive medical-device experience, mostly in the US, building and growing companies in pain monitoring, orthopedics, robotic spine surgery, advanced wound healing and urology.
At Mazor Robotics (NASDAQ: MZOR; recently sold to Medtronic for $1.6B) he was hired as the second employee in the US, rose quickly through the ranks to senior management positions, and helped develop and lead the company’s nation-wide presence and operations.
Sagi was also the founding CEO of Perfuzia Medical, where he took the company from inception through seed and A-round financing, product development, IP development, clinical studies and strategic partnerships.
In his position as VP at SRS Medical Sagi led the international commercialization of an advanced urological technology, developed at an investment of over $100M.
Prior to his medical-device career Sagi served in an elite Navy unit of the IDF (Israel Defense Forces), where he attained the rank of Captain.
He holds an MBA Cum-Laude from Babson College (Boston, MA, USA) in entrepreneurship and international business, and an MSc in Biomedical Engineering from Tel Aviv University (Israel) with a full merit scholarship; his Master’s thesis was spun out as a startup company funded by Israel’s Office of the Chief Scientist. Sagi also holds a BSc in Electrical and Electronics Engineering from TAU (dean’s list, merit scholarship), and is a graduate of Israel’s Naval Officer Academy in Haifa.
He has several scientific and medical publications, and holds numerous patents worldwide.
Prof. Yehoshua (Shuki) Shemer, MD – Board Director
Professor Shemer is Chairman of the Board of Assuta Israel, the country’s largest private hospital network. He is also Director of the Israeli Center for Technology Assessment in Health Care (ICTAHC) at the Gertner Institute, which is a research unit serving the Israeli Ministry of Health. A graduate of the Hebrew University and Hadassah School of Medicine, he is a foremost specialist in medical technology management and serves in that capacity as a faculty member at the Tel Aviv University Business School.
Over the years, Professor Shemer has served as Surgeon General of the IDF, Director General of Israel’s Ministry of Health, and CEO of Maccabi HMO. He has led a number of national reform committees and has been an active participant in more than a hundred scientific meetings both in Israel and abroad.
A prolific writer and editor, he has published extensively in prominent professional publications, authored numerous chapters and 6 books on trauma, terror, health reform and technology assessment.
Morris Laster, MD – Board Director
Dr. Laster is a healthcare executive/entrepreneur with over 25 years of experience in the biopharmaceutical and medical-device industries.
Currently he is a Venture Partner responsible for Medtech investments at OurCrowd, and the Founder of Clil Medical and Xerem Medical.
Dr. Laster has founded 6 companies that have gone public in the US, UK and Israel. He was the Founder and Director of Kitov Pharmaceuticals (TASE: KTOV), Founding CEO of BioLineRX (dually-listed on NASDAQ and TASE: BLRX), and Chairman and CEO of Keryx Biopharmaceuticals (NASDAQ:KERX) – where he led the first simultaneous NASDAQ/AIM listing in 2000.
Dr. Laster began his entrepreneurial career as a VP of medical venture capital at Paramount Capital in NYC. While in that capacity he founded three companies that went public: XTL Therapeutics (NASDAQ:XTLB) – which developed hepatitis B and C antibodies in programs that were licensed to Cubist, Progenitor (NASDAQ:PGEN), and Neose Technologies (NASDAQ: NTEC).
He received his MD from Downstate Medical Center, Brooklyn, NY in 1990 and a BS in Biology from SUNY Albany.
Lior Buchman, CPA – Board Director
Mr. Buchman has over 20 years of experience in senior corporate financing, mergers & acquisitions, investor relations, operational and business development. Currently the CFO of Integra Holdings Ltd, he has served as CFO of numerous international medical-device and life sciences companies – including Stryker GI (formerly Sightline Technologies), and others.
Mr. Buchman has extensive experience in equity and debt financing with over $150 Million aggregate capital raised and M&A including post-closing integration into the acquiring organizations.
He is a CPA (Isr.), and holds a BA in Accounting and Economics from the University of Haifa.